# ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study

> **NCT05596409** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Stemline Therapeutics, Inc.** · enrollment: 61 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Elacestrant

## Key facts

- **NCT ID:** NCT05596409
- **Lead sponsor:** Stemline Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-19
- **Primary completion:** 2026-11
- **Final completion:** 2027-11
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05596409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05596409, "ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study". Retrieved via AI Analytics 2026-05-20 from https://api.ai-analytics.org/clinical/NCT05596409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*